AI Therapeutics Stock

ai-therapeutics.comHealthcareFounded: 2013Funding to Date: $98MM

AI Therapeutics is the developer of a deep learning platform designed to synthesize public and proprietary data on drugs and diseases and finds new indications for our library of new chemical entities.

Register for Details

For more details on financing and valuation for AI Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for AI Therapeutics.

Register Today

Team

Management Team

Henri Lichenstein Ph.D
President, CSO & Chief Executive Officer
Jonathan Rothberg Ph.D
Co-Founder & Board Member
Paul Beckett Ph.D
Senior Director of Drug Discovery
Tian Xu Ph.D
Co-Founder & Scientific Advisor

Board Members

George Rehm JD
Jonathan Rothberg Ph.D
Gregg Fergus
4Catalyzer

Other companies like AI Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 

News

LAM Therapeutics, a Guilford, Conn.-based developer of drugs for cancer and rare diseases, closed $58M in Series C financing. The backers were not disclosed. The company intends to use the funds to advance its drugs. Led by Henri Lichenstein, Ph.D., and Dr. Tian Xu, LAM Therapeutics develops precision therapeutics and companion diagnostics for cancer and …